|
US4418068A
(en)
|
1981-04-03 |
1983-11-29 |
Eli Lilly And Company |
Antiestrogenic and antiandrugenic benzothiophenes
|
|
TW366342B
(en)
|
1992-07-28 |
1999-08-11 |
Lilly Co Eli |
The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
|
|
US5565215A
(en)
|
1993-07-23 |
1996-10-15 |
Massachusettes Institute Of Technology |
Biodegradable injectable particles for imaging
|
|
US5478847A
(en)
|
1994-03-02 |
1995-12-26 |
Eli Lilly And Company |
Methods of use for inhibiting bone loss and lowering serum cholesterol
|
|
GB9412273D0
(en)
|
1994-06-18 |
1994-08-10 |
Univ Nottingham |
Administration means
|
|
US6007845A
(en)
|
1994-07-22 |
1999-12-28 |
Massachusetts Institute Of Technology |
Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
|
|
US6413539B1
(en)
|
1996-10-31 |
2002-07-02 |
Poly-Med, Inc. |
Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
|
|
US5628984A
(en)
|
1995-07-31 |
1997-05-13 |
University Of North Carolina At Chapel Hill |
Method of detecting lung disease
|
|
US5780497A
(en)
|
1996-04-19 |
1998-07-14 |
American Home Products Corporation |
2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
|
|
TW397821B
(en)
|
1996-04-19 |
2000-07-11 |
American Home Produits Corp |
3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
|
|
US5998402A
(en)
|
1996-04-19 |
1999-12-07 |
American Home Products Corporation |
2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
|
|
US5880137A
(en)
|
1996-04-19 |
1999-03-09 |
American Home Products Corporation |
2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
|
|
US6005102A
(en)
|
1997-10-15 |
1999-12-21 |
American Home Products Corporation |
Aryloxy-alkyl-dialkylamines
|
|
UA68365C2
(en)
|
1997-11-06 |
2004-08-16 |
Wyeth Corp |
Peroral contraception by combination of anti-estrogen and progestin
|
|
US6326392B1
(en)
|
1997-11-06 |
2001-12-04 |
American Home Products Corporation |
Anti-estrogen plus progestin containing oral contraceptives
|
|
US6583170B1
(en)
|
1998-05-15 |
2003-06-24 |
Wyeth |
2-Phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol and estrogen formulations
|
|
US6479535B1
(en)
|
1998-05-15 |
2002-11-12 |
Wyeth |
2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
|
|
US6287588B1
(en)
|
1999-04-29 |
2001-09-11 |
Macromed, Inc. |
Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
|
|
CO5271697A1
(es)
|
2000-01-12 |
2003-04-30 |
Pfizer Prod Inc |
Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
|
|
CO5271709A1
(es)
|
2000-01-12 |
2003-04-30 |
Pfizer Prod Inc |
Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
|
|
CO5271696A1
(es)
|
2000-01-12 |
2003-04-30 |
Pfizer Prod Inc |
Procedimiento para reducir la morbilidad y el riesgo de mortalidad
|
|
CO5251465A1
(es)
|
2000-01-26 |
2003-02-28 |
Pfizer Prod Inc |
Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol
|
|
EP1268477B1
(en)
|
2000-03-15 |
2010-04-21 |
Sanofi-Aventis Deutschland GmbH |
Substituted beta-carbolines with ikb-kinase inhibiting activity
|
|
US20020013327A1
(en)
|
2000-04-18 |
2002-01-31 |
Lee Andrew G. |
Compositions and methods for treating female sexual dysfunction
|
|
US6589549B2
(en)
|
2000-04-27 |
2003-07-08 |
Macromed, Incorporated |
Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
|
|
US6495164B1
(en)
|
2000-05-25 |
2002-12-17 |
Alkermes Controlled Therapeutics, Inc. I |
Preparation of injectable suspensions having improved injectability
|
|
EP1296674A2
(en)
|
2000-07-06 |
2003-04-02 |
Wyeth |
Use of substituted indole compounds for increasing nitric oxide synthase activity
|
|
US6509332B2
(en)
|
2000-07-06 |
2003-01-21 |
Wyeth |
Methods of treating excessive intraocular pressure
|
|
JP2004502729A
(ja)
|
2000-07-06 |
2004-01-29 |
ワイス |
Ssriおよびエストロゲン剤の組み合わせ
|
|
WO2002003989A2
(en)
|
2000-07-06 |
2002-01-17 |
Wyeth |
Use of substituted indole compounds for treating sphincter incontinence
|
|
AU2001271706A1
(en)
|
2000-07-06 |
2002-01-21 |
American Home Products Corporation |
Use of substituted indole compounds for treating breast disorders
|
|
AR030064A1
(es)
|
2000-07-06 |
2003-08-13 |
Wyeth Corp |
Metodos para inhibir los efectos uterotroficos de los agentes estrogenicos
|
|
AU2001273125A1
(en)
|
2000-07-06 |
2002-01-21 |
American Home Products Corporation |
Combinations of bisphosphonates, estrogenic agents and optionally estrogens
|
|
EP1359940A2
(en)
|
2000-07-06 |
2003-11-12 |
Wyeth |
Combinations of statins, estrogenic agents and optionally estrogens
|
|
WO2002003988A2
(en)
|
2000-07-06 |
2002-01-17 |
Wyeth |
Use of substituted indole compounds for treating neuropeptide y-related conditions
|
|
AU2001271784A1
(en)
|
2000-07-06 |
2002-01-21 |
Wyeth |
Therapy for prosthesis-related bone degeneration
|
|
EP1177787A3
(en)
|
2000-07-28 |
2003-09-10 |
Pfizer Products Inc. |
Use of an estrogen agonist/antagonist for treating cataracts
|
|
ATE278421T1
(de)
|
2000-08-11 |
2004-10-15 |
Wyeth Corp |
Verfahren zur behandlung eines östrogenrezeptor positives karzinoms
|
|
EP1192945A3
(en)
|
2000-09-21 |
2004-03-03 |
Pfizer Products Inc. |
Use of an estrogen agonist/antagonist for treating osteoarthritis
|
|
IL145838A
(en)
|
2000-10-16 |
2008-11-03 |
Pfizer Prod Inc |
Use of an estrogen agonist/antagonist for the manufacture of a medicament for treating vaginitis
|
|
EP2316490A3
(en)
|
2000-10-31 |
2012-02-01 |
PR Pharmaceuticals, Inc. |
Methods and compositions for enhanced delivery of bioactive molecules
|
|
AU781168B2
(en)
|
2001-01-26 |
2005-05-12 |
Pfizer Products Inc. |
Method of treating certain cancers using an estrogen agonist/antagonist
|
|
GB0122318D0
(en)
|
2001-09-14 |
2001-11-07 |
Novartis Ag |
Organic compounds
|
|
NZ534069A
(en)
|
2002-01-22 |
2007-03-30 |
Warner Lambert Co |
2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer
|
|
EP1590341B1
(en)
*
|
2003-01-17 |
2009-06-17 |
Warner-Lambert Company LLC |
2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
|
|
US20050009910A1
(en)
|
2003-07-10 |
2005-01-13 |
Allergan, Inc. |
Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug
|
|
ES2246694B1
(es)
|
2004-04-29 |
2007-05-01 |
Instituto Cientifico Y Tecnologico De Navarra, S.A. |
Nanoparticulas pegiladas.
|
|
BRPI0510485A
(pt)
|
2004-04-30 |
2007-11-13 |
Allergan Inc |
implantes inibidores de tirosina cinase intravìtreos biodegradáveis
|
|
US7771742B2
(en)
|
2004-04-30 |
2010-08-10 |
Allergan, Inc. |
Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
|
|
US20050244469A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Extended therapeutic effect ocular implant treatments
|
|
JPWO2006008874A1
(ja)
|
2004-05-21 |
2008-05-01 |
萬有製薬株式会社 |
アミノチアゾ−ル骨格を有するCdk4、6選択的阻害剤
|
|
US7399767B2
(en)
|
2005-01-21 |
2008-07-15 |
Ortho-Mcneil Pharmaceutical, Inc. |
Heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors
|
|
US20070071756A1
(en)
|
2005-09-26 |
2007-03-29 |
Peyman Gholam A |
Delivery of an agent to ameliorate inflammation
|
|
US7946916B2
(en)
|
2006-01-12 |
2011-05-24 |
Waterleaf Ltd. |
Variable payout wager games
|
|
WO2007084418A2
(en)
|
2006-01-13 |
2007-07-26 |
Surmodics, Inc. |
Microparticle containing matrices for drug delivery
|
|
CA2640678C
(en)
|
2006-02-03 |
2015-03-31 |
Bionomics Limited |
Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors
|
|
US20080166411A1
(en)
|
2006-04-10 |
2008-07-10 |
Pfizer Inc |
Injectable Depot Formulations And Methods For Providing Sustained Release Of Poorly Soluble Drugs Comprising Nanoparticles
|
|
WO2009100176A2
(en)
|
2008-02-07 |
2009-08-13 |
Abbott Laboratories |
Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
|
|
CA2726114A1
(en)
|
2008-06-11 |
2009-12-17 |
Genentech, Inc. |
Diazacarbazoles and methods of use
|
|
AU2009284098B2
(en)
*
|
2008-08-22 |
2012-03-29 |
Astex Therapeutics Ltd. |
Pyrrolopyrimidine compounds as CDK inhibitors
|
|
WO2010043633A1
(en)
|
2008-10-15 |
2010-04-22 |
Palau Pharma, S. A. |
2h-pyrazolo [4,3-d]pyrimidin-5-amine derivatives as h4 histamine receptor antagonists for the treatment of allergic, immunological and inflammatory diseases
|
|
WO2010091187A2
(en)
|
2009-02-04 |
2010-08-12 |
The Brigham And Women's Hospital, Inc. |
Polymeric nanoparticles with enhanced drug-loading and methods of use thereof
|
|
US10952965B2
(en)
|
2009-05-15 |
2021-03-23 |
Baxter International Inc. |
Compositions and methods for drug delivery
|
|
CN102713618B
(zh)
|
2009-09-16 |
2015-07-15 |
新基阿维罗米克斯研究公司 |
蛋白激酶复合物和抑制剂
|
|
UY33227A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
|
|
US20130071349A1
(en)
|
2010-03-02 |
2013-03-21 |
Allergan, Inc. |
Biodegradable polymers for lowering intraocular pressure
|
|
EP3205648A1
(en)
|
2010-06-10 |
2017-08-16 |
Seragon Pharmaceuticals, Inc. |
Estrogen receptor modulators and uses thereof
|
|
US8853423B2
(en)
|
2010-06-17 |
2014-10-07 |
Seragon Pharmaceuticals, Inc. |
Indane estrogen receptor modulators and uses thereof
|
|
GB2483736B
(en)
|
2010-09-16 |
2012-08-29 |
Aragon Pharmaceuticals Inc |
Estrogen receptor modulators and uses thereof
|
|
US10005750B2
(en)
|
2010-10-06 |
2018-06-26 |
J-Pharma Co., Ltd. |
Developing potent urate transporter inhibitors: compounds designed for their uricosuric action
|
|
KR102186969B1
(ko)
*
|
2010-10-25 |
2020-12-04 |
쥐원 쎄라퓨틱스, 인크. |
Cdk 억제제
|
|
US8691830B2
(en)
|
2010-10-25 |
2014-04-08 |
G1 Therapeutics, Inc. |
CDK inhibitors
|
|
US8829102B2
(en)
|
2010-10-27 |
2014-09-09 |
Cabot Corporation |
High loading carbon black masterbatch for pressure pipe applications
|
|
US9840515B2
(en)
|
2010-12-09 |
2017-12-12 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Protein kinase D inhibitors
|
|
EA026134B1
(ru)
|
2010-12-16 |
2017-03-31 |
Ф. Хоффманн-Ля Рош Аг |
Трициклические ингибиторы pi3k и способы их применения
|
|
CA2819299A1
(en)
|
2010-12-24 |
2012-06-28 |
Merck Sharp & Dohme B.V. |
N-substituted azetidine derivatives
|
|
CN103889986B
(zh)
|
2011-09-30 |
2017-07-21 |
C&C新药研究所 |
新杂环衍生物及其应用
|
|
EP2791132A4
(en)
|
2011-12-14 |
2015-08-05 |
Seragon Pharmaceuticals Inc |
ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
|
|
BR112014014767A2
(pt)
|
2011-12-16 |
2017-06-13 |
Olema Pharmaceuticals Inc |
novos compostos de benzopirano, composições e usos dos mesmos
|
|
EP3216792B1
(en)
|
2012-03-29 |
2020-05-27 |
G1 Therapeutics, Inc. |
Lactam kinase inhibitors
|
|
US20140107025A1
(en)
|
2012-04-16 |
2014-04-17 |
Jade Therapeutics, Llc |
Ocular drug delivery system
|
|
CA2870019C
(en)
|
2012-04-26 |
2020-08-18 |
Francis Xavier Tavares |
Synthesis of lactams
|
|
CN104145514B
(zh)
|
2012-08-01 |
2018-03-13 |
华为技术有限公司 |
用于同步的方法、装置及系统
|
|
BR112015005878A2
(pt)
|
2012-09-17 |
2017-07-04 |
Bind Therapeutics Inc |
nanopartículas terapêuticas compreendendo agente terapêutico e métodos de preparar e usar as mesmas
|
|
AU2013317899A1
(en)
|
2012-09-20 |
2015-05-07 |
Akina, Inc. |
Biodegradable microcapsules containing filling material
|
|
RU2702908C2
(ru)
|
2012-11-01 |
2019-10-14 |
Инфинити Фармасьютикалз, Инк. |
Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
|
|
KR101747587B1
(ko)
*
|
2013-03-15 |
2017-06-14 |
노벨리스 인크. |
감쇄된 광택 마감을 갖는 압연 표면
|
|
WO2014144596A2
(en)
|
2013-03-15 |
2014-09-18 |
G1 Therapeutics, Inc. |
Transient protection of hematopoietic stem and progenitor cells against ionizing radiation
|
|
CA2906157C
(en)
*
|
2013-03-15 |
2022-05-17 |
G1 Therapeutics, Inc. |
Highly active anti-neoplastic and anti-proliferative agents
|
|
JP6430483B2
(ja)
|
2013-03-15 |
2018-11-28 |
ジー1、セラピューティクス、インコーポレイテッドG1 Therapeutics, Inc. |
化学療法の間の正常細胞の一時的な保護
|
|
WO2014165308A2
(en)
|
2013-04-01 |
2014-10-09 |
Allergan, Inc. |
Microsphere drug delivery system for sustained intraocular release
|
|
AP2015008858A0
(en)
|
2013-05-28 |
2015-11-30 |
Astrazeneca Ab |
Chemical compounds
|
|
EA031077B1
(ru)
|
2013-06-19 |
2018-11-30 |
Серагон Фармасьютикалз, Инк. |
Модулятор рецептора эстрогена и его применения
|
|
WO2014203132A1
(en)
|
2013-06-19 |
2014-12-24 |
Olema Pharmaceuticals, Inc. |
Substituted benzopyran compounds, compositions and uses thereof
|
|
WO2014203129A1
(en)
|
2013-06-19 |
2014-12-24 |
Olema Pharmaceuticals, Inc. |
Combinations of benzopyran compounds, compositions and uses thereof
|
|
BR112015030595A2
(pt)
|
2013-06-19 |
2017-07-25 |
Seragon Pharmaceuticals Inc |
moduladores de receptor de estrogênio de azetidina e usos dos mesmos
|
|
WO2015061407A1
(en)
|
2013-10-24 |
2015-04-30 |
Francis Xavier Tavares |
Process for synthesis of lactams
|
|
US9481591B1
(en)
|
2013-12-16 |
2016-11-01 |
Barbara Blake |
Device and process to treat and disinfect sewage, food processing wastewater and other biologically contaminated water
|
|
SG11201607334YA
(en)
|
2014-03-13 |
2016-10-28 |
Hoffmann La Roche |
Therapeutic combinations with estrogen receptor modulators
|
|
WO2015161283A1
(en)
|
2014-04-17 |
2015-10-22 |
G1 Therapeutics, Inc. |
Tricyclic lactams for use in hspc-sparing treatments for rb-positive abnormal cellular proliferation
|
|
RU2671494C2
(ru)
|
2014-05-28 |
2018-11-01 |
Шанхай Фокон Фармасьютикал Ко., Лтд |
Некоторые ингибиторы протеинкиназы
|
|
EP3191098A4
(en)
|
2014-09-12 |
2018-04-25 |
G1 Therapeutics, Inc. |
Combinations and dosing regimes to treat rb-positive tumors
|
|
WO2016040848A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
|
|
TWI784255B
(zh)
|
2014-12-18 |
2022-11-21 |
瑞士商赫孚孟拉羅股份公司 |
四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
|
|
CN109789143A
(zh)
*
|
2016-07-01 |
2019-05-21 |
G1治疗公司 |
基于嘧啶的抗增殖剂
|
|
WO2018005863A1
(en)
*
|
2016-07-01 |
2018-01-04 |
G1 Therapeutics, Inc. |
Pyrimidine-based compounds for the treatment of cancer
|
|
US11865176B2
(en)
|
2016-11-08 |
2024-01-09 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods of modulating anti-tumor immunity
|
|
CA3045037A1
(en)
|
2016-12-08 |
2018-06-14 |
Icahn School Of Medicine At Mount Sinai |
Compositions and methods for treating cdk4/6-mediated cancer
|